BCDA

BioCardia Inc

Add to Watchlist

Advanced Chart

2.350

+0.04(1.732%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.3963

Open

2.330

VWAP

2.36

Vol

30.85K

Mkt Cap

12.81M

Low

2.3202

Amount

72.86K

EV/EBITDA(TTM)

Total Shares

1.83M

11.86M

EV/OCF(TTM)

P/S(TTM)

2.73K

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q4

FY2024Q3

22.50K

+73.08%

200.00K

-43.98%

Estimates Revision

The market is revising No Change the revenue expectations for BioCardia, Inc. (BCDA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -2.89%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-2.89%

In Past 3 Month

1 Analyst Rating

155.32% Upside

Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

155.32% Upside

Current: 2.350

Low

6.00

Averages

6.00

High

6.00

155.32% Upside

Current: 2.350

Low

6.00

Averages

6.00

High

6.00

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$25

2024-12-18

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$25

2024-12-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$25

2024-11-14

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$25

2024-11-14

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$25

2024-10-28

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$25

2024-10-28

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$25

2024-08-21

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$25

2024-08-21

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$4 → $25

2024-08-16

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$4 → $25

2024-08-16

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for BioCardia Inc (BCDA.O) is -2.04, compared to its 5-year average forward P/E of -3.07. For a more detailed relative valuation and DCF analysis to assess BioCardia Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.07

Current PE

-2.04

Overvalued PE

-0.60

Undervalued PE

-5.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.00

Undervalued EV/EBITDA

-2.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

130.15

Current PS

0.00

Overvalued PS

320.03

Undervalued PS

-59.73

Financials

Annual

Quarterly

FY2025Q1

YoY :

-100.00%

0.00

Total Revenue

FY2025Q1

YoY :

+19.82%

-2.73M

Operating Profit

FY2025Q1

YoY :

+19.63%

-2.71M

Net Income after Tax

FY2025Q1

YoY :

-56.30%

-0.59

EPS - Diluted

FY2025Q1

YoY :

-100.00%

N/A

Free Cash Flow

FY2025Q1

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2025Q1

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q1

YoY :

-100.00%

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 6000.63% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

6.5K

USD

0-12

Months

0.0

USD

Bought

0-3

365.9K

USD

Months

3-6

677.2K

USD

Months

6-9

6.9K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 6000.63% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

6.5K

USD

0-12

Months

0.0

USD

Bought

0-3

365.9K

USD

Months

3-6

677.2K

USD

Months

6-9

6.9K

USD

Months

0-12

0.0

USD

Months

BCDA News & Events

Events Timeline

2025-07-24 (ET)

2025-07-24

09:08:36

BioCardia submits CardiAMP for consultation with Japan's PMDA

2025-07-16 (ET)

2025-07-16

08:50:35

Henry Ford Health initiates enrollment for BioCardia's CardiAMP HF II study

2025-06-25 (ET)

2025-06-25

08:04:09

BioCardia announces new U.S. patent for Helix Biotherapeutic delivery system

News

9.0

07-16Newsfilter

Henry Ford Health Initiates Patient Enrollment for BioCardia's CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

9.0

06-25Newsfilter

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System

1.0

05-21Newsfilter

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

People Also Watch

CMCT

Creative Media & Community Trust Corporation

BP Prudhoe Bay Royalty Trust

PS International Group Ltd

mF International Limited

Haoxi Health Technology Ltd

1.350

USD

-2.17%

FAQ

What is BioCardia Inc (BCDA) stock price today?

The current price of BCDA is 2.35 USD — it has increased 1.73 % in the last trading day.

BCDA

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

BCDA News & Events

Events Timeline

News

People Also Watch

FAQ

What is BioCardia Inc (BCDA) stock price today?

What is BioCardia Inc (BCDA)'s business?

What is the price predicton of BCDA Stock?

What is BioCardia Inc (BCDA)'s revenue for the last quarter?

What is BioCardia Inc (BCDA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for BioCardia Inc (BCDA)'s fundamentals?

How many employees does BioCardia Inc (BCDA). have?

What is BioCardia Inc (BCDA) market cap?